MIR-155 overexpression promotes genomic instability by reducing high-fidelity polymerase delta expression and activating error-prone DSB repair

Molecular Cancer Research

Volumn 14, Issue 4, 2016, Pages 363-373

  Czochor, Jennifer R ^a   Sulkowski, Parker ^a   Glazer, Peter M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA DIRECTED DNA POLYMERASE DELTA; MESSENGER RNA; MICRORNA 155; PROTEIN MLH1; PROTEIN MSH6; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHRL1; DNA DIRECTED DNA POLYMERASE GAMMA; FOXO3 PROTEIN, HUMAN; MICRORNA; MIRN155 MICRORNA, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; DNA END JOINING REPAIR; DNA REPAIR; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; IN VITRO STUDY; IN VIVO STUDY; MISMATCH REPAIR; MOUSE; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; ANIMAL; CELL LINE; GENETICS; HUMAN; METABOLISM; UPREGULATION;

ANIMALS; CELL LINE; DNA POLYMERASE III; DNA REPAIR; FORKHEAD BOX PROTEIN O3; GENOMIC INSTABILITY; HUMANS; MICE; MICRORNAS; MUTATION RATE; UP-REGULATION;

EID: 84963891316     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-15-0399     Document Type: Article

References (61)

1. Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ. Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biol Ther 2011;12:908-14.
2. Bruning U, Cerone L, Neufeld Z, Fitzpatrick SF, Cheong A, Scholz CC, et al. Micro RNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia. Mol Cell Biol 2011;31:4087-96.
3. Papaconstantinou IG, Manta A, Gazouli M, Lyberopoulou A, Lykoudis PM, Polymeneas G, et al. Expression of micro RNAs in patients with pancreatic cancer and its prognostic significance. Pancreas 2013;42: 67-71.
4. Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of micro RNA-21 and micro RNA-155 in colorectal cancer. Oncology 2010;79:313-20.
5. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique micro RNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.
6. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. Micro RNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70.
7. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, et al. Expression profiling identifies micro RNA signature in pancreatic cancer. Int J Cancer 2007;120:1046-54.
8. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 2005;102:3627-32.
9. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, et al. Nanoparticle-based therapy in an in vivo micro RNA-155 (miR-155)- dependent mouse model of lymphoma. Proc Natl Acad Sci U S A 2012; 109:E1695-704.
10. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, et al. Micro RNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010;285:17869-79.
11. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A 2009; 106:7113-8.
12. Wang Y, Scheiber MN, Neumann C, Calin GA, Zhou D. Micro RNA regulation of ionizing radiation-induced premature senescence. Int J Radiat Oncol Biol Phys 2011;81:839-48.
13. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, et al. Micro RNA-155 functions as an Oncomi R in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010;70:3119-27.
14. Gasparini P, Lovat F, Fassan M, Casadei L, Cascione L, Jacob NK, et al. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci U S A 2014;111:4536-41.
15. Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F, et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A 2010;107:6982-7.
16. Tili E, Michaille JJ, Wernicke D, Alder H, Costinean S, Volinia S, et al. Mutator activity induced by micro RNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci U S A 2011;108:4908-13.
17. Rogers FA, Manoharan M, Rabinovitch P, Ward DC, Glazer PM. Peptide conjugates for chromosomal gene targeting by triplex-forming oligonucleotides. Nucleic Acids Res 2004;32:6595-604.
18. Singleton BK, Priestley A, Steingrimsdottir H, Gell D, Blunt T, Jackson SP, et al. Molecular and biochemical characterization of xrs mutants defective in Ku80. Mol Cell Biol 1997;17:1264-73.
19. Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 2009;69:6381-6.
20. Bindra RS, Goglia AG, Jasin M, Powell SN. Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells. Nucleic Acids Res 2013;41:e115.
21. Nakanishi K, Cavallo F, Brunet E, Jasin M. Homologous recombination assay for interstrand cross-link repair. Methods Mol Biol 2011;745:283-91.
22. Hegan DC, Narayanan L, Jirik FR, Edelmann W, Liskay RM, Glazer PM. Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6. Carcinogenesis 2006; 27:2402-8.
23. Narayanan L, Fritzell JA, Baker SM, Liskay RM, Glazer PM. Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2. Proc Natl Acad Sci U S A 1997;94:3122-7.
24. Leach EG, Gunther EJ, Yeasky TM, Gibson LH, Yang-Feng TL, Glazer PM. Frequent spontaneous deletions at a shuttle vector locus in transgenicmice. Mutagenesis 1996;11:49-56.
25. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, et al. Regulation of the germinal center response bymicro RNA-155. Science 2007;316:604-8.
26. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. Micro RNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 2009;69:1221-9.
27. Nagel ZD, Margulies CM, Chaim IA, McRee SK, Mazzucato P, Ahmad A, et al. Multiplexed DNA repair assays for multiple lesions and multiple doses via transcription inhibition and transcriptional mutagenesis. Proc Natl Acad Sci U S A 2014;111:E1823-32.
28. Bau DT, Fu YP, Chen ST, Cheng TC, Yu JC, Wu PE, et al. Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1. Cancer Res 2004; 64:5013-9.
29. Li YH, Wang X, Pan Y, Lee DH, Chowdhury D, Kimmelman AC. Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response. PLoS One 2012;7:e39588.
30. Sears CR, Turchi JJ. Complex cisplatin-double strand break (DSB) lesions directly impair cellular non-homologous end-joining (NHEJ) independent of downstream damage response (DDR) pathways. J Biol Chem 2012;287:24263-72.
31. Wang HC, Chou WC, Shieh SY, Shen CY. Ataxia telangiectasia mutated and checkpoint kinase 2 regulate BRCA1 to promote the fidelity of DNA endjoining. Cancer Res 2006;66:1391-400.
32. Zhong Q, Chen CF, Chen PL, Lee WH. BRCA1 facilitates microhomology mediated end joining of DNA double strand breaks. J Biol Chem 2002;277: 28641-7.
33. Soong CP, Breuer GA, Hannon RA, Kim SD, Salem AF, Wang G, et al. Development of a novel method to create double-strand break repair fingerprints using next-generation sequencing. DNA Repair (Amst) 2015; 26:44-53.
34. Bennardo N, Cheng A, Huang N, Stark JM. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet 2008;4:e1000110.
35. Fattah FJ, Kweon J, Wang Y, Lee EH, Kan Y, Lichter N, et al. A role for XLF in DNA repair and recombination in human somatic cells. DNA Repair (Amst) 2014;15:39-53.
36. Kaushik Tiwari M, Rogers FA. XPD-dependent activation of apoptosis in response to triplex-induced DNA damage. Nucleic Acids Res 2013;41: 8979-94.
37. Rogers FA, Lin SS, Hegan DC, Krause DS, Glazer PM. Targeted gene modification of hematopoietic progenitor cells in mice following systemic administration of a PNA-peptide conjugate. Mol Ther 2012;20:109-18.
38. Hirano T, Yamaguchi R, Asami S, Iwamoto N, Kasai H. 8-hydroxyguanine levels in nuclear DNA and its repair activity in rat organs associated with age. J Gerontol A Biol Sci Med Sci 1996;51:B303-7.
39. Russo MT, De Luca G, Degan P, Bignami M. Different DNA repair strategies to combat the threat from 8-oxoguanine. Mutat Res 2007;614:69-76.
40. Russo MT, De Luca G, Degan P, Parlanti E, Dogliotti E, Barnes DE, et al. Accumulation of the oxidative base lesion 8-hydroxyguanine in DNA of tumor-prone mice defective in both the Myh and Ogg1 DNA glycosylases. Cancer Res 2004;64:4411-4.
41. McVey M, Lee SE. MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. Trends Genet 2008;24:529-38.
42. Nussenzweig A, Nussenzweig MC. A backup DNA repair pathway moves to the forefront. Cell 2007;131:223-5.
43. Truong LN, Li Y, Shi LZ, Hwang PY, He J, Wang H, et al. Microhomology mediated End Joining and Homologous Recombination share the initial end resection step to repair DNA double-strand breaks inmammalian cells. Proc Natl Acad Sci U S A 2013;110:7720-5.
44. Ling N, Gu J, Lei Z, Li M, Zhao J, Zhang HT, et al. micro RNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma. Oncol Rep 2013;30:2111-8.
45. McGovern UB, Francis RE, Peck B, Guest SK, Wang J, Myatt SS, et al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther 2009;8:582-91.
46. Gomes AR, Zhao F, Lam EW. Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance. Chin J Cancer 2013;32:365-70.
47. Laoukili J, Kooistra MR, Brás A, Kauw J, Kerkhoven RM, Morrison A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005;7:126-36.
48. Uchimura A, Hidaka Y, Hirabayashi T, Hirabayashi M, Yagi T. DNA polymerase delta is required for early mammalian embryogenesis. PLoS One 2009;4:e4184.
49. Castrillon DH, Miao L, Kollipara R, Horner JW, De Pinho RA. Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science 2003;301:215-8.
50. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, et al. FoxOs are lineagerestricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007;128:309-23.
51. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007;128:325-39.
52. Albertson TM, Ogawa M, Bugni JM, Hays LE, Chen Y, Wang Y, et al. DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice. Proc Natl Acad Sci U S A 2009;106:17101-4.
53. Goldsby RE, Hays LE, Chen X, Olmsted EA, Slayton WB, Spangrude GJ, et al. High incidence of epithelial cancers in mice deficient for DNA polymerase delta proofreading. Proc Natl Acad Sci U S A 2002;99:15560-5.
54. Venkatesan RN, Hsu JJ, Lawrence NA, Preston BD, Loeb LA. Mutator phenotypes caused by substitution at a conserved motif A residue in eukaryotic DNA polymerase delta. J Biol Chem 2006;281:4486-94.
55. Ito A, Koshikawa N, Mochizuki S, Omura K, Takenaga K. Hypoxia-inducible factor-1 mediates the expression of DNA polymerase iota in human tumor cells. Biochem Biophys Res Commun 2006;351:306-11.
56. Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MI, et al. Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair. Nature 2015;518:258-62.
57. Kent T, Chandramouly G, McDevitt SM, Ozdemir AY, Pomerantz RT. Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase theta. Nat Struct Mol Biol 2015;22:230-7.
58. Choi YE, Pan Y, Park E, Konstantinopoulos P, De S, D'Andrea A, et al. Micro RNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability. Elife 2014;3:e02445.
59. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting micro RNA. N Engl J Med 2013;368:1685-94.
60. Shibata C, Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, Takata A, et al. et al. Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma. Mol Cell Ther 2013;1:5.
61. Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, et al. Micro RNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 2015;518:107-10.